Member news

Coulter Partners successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).

Coulter Partners successfully completed search assignments for Augustine Therapeutics NV.

Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.

Their vanguard, breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics.

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20 million.

OutSee, announced it has secured £1.8 million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026

The average size of artificial intelligence (AI) deals was significantly higher than deals across the wider UK equity market in 2024, underlining the continued focus on the sector, reveals the British Business Bank’s annual Small Business Equity Tracker, published today.

Gastronomica, Pioneer Group’s cutting-edge food tech hub, was crowned winner of the Innovative Workplace Design award at the Property Week and Construction News Life Sciences & Research Clusters Awards.

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit

Discovery Park opened its doors for the East Kent Science Jamboree, hosting a record-breaking 1,500 children from 51 Kent schools for a two-day science spectacular.

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

Present Made, Eddington, is leading the way with Cambridge’s first purpose-built, large-scale corporate letting scheme – a pioneering development that brings 21st-century executive living to one of the UK’s most dynamic science and technology hubs.

The new site reflects Stratagem’s growth as a forward-thinking IP partner, offering clarity, simplicity and relevance across every stage of the client journey.

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.